More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Simvastatin [79902-63-9]
Chemical Structure
Chemical Structure
Chemical Structure

Simvastatin [79902-63-9]

Research Use Only
AG-CN2-0052
AdipoGen Life Sciences
CAS Number79902-63-9
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight418.6
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Simvastatin
  • Delivery Days Customer
    10
  • CAS Number
    79902-63-9
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Molecular Formula
    C25H38O5
  • Molecular Weight
    418.6
  • Scientific Description
    Chemical. CAS: 79902-63-9. Formula: C25H38O5. MW: 418.6. Synthetic. Synthetic analog of Lovastatin (Prod. No. AG-CN2-0051 http://www.adipogen.com/ag-cn2-0051/lovastatin.html ). Potent competitive HMG-CoA reductase inhibitor. Anti-hypercholesterolemic agent. Cholesterol/isoprenoid biosynthesis inhibitor. Blocks the production of mevalonate, a critical compound in the production of cholesterol and isoprenoids. Inhibits the isoprenylation of Ras and Rho family GTPases. Smooth muscle cell proliferation inhibitor. Anti-adhesive, immunomodulatory and anti-inflammatory compound. Proteasome modulator. Stimulates bone formation. Apoptosis inducer. Anticancer compound. Increases cellular resistance to anticancer agents such as doxorubicin and etoposides (Prod. No. AG-CR1-3572 http://www.adipogen.com/ag-cr1-3572/etoposide.html ). Suppresses ICAM-1-LFA-1 interactions, which blocks virus replication and infection. Anti-hypertensive agent. Suppresses TNF-induced NF-kappaB activation. - Synthetic analog of Lovastatin (Prod. No. AG-CN2-0051 http://www.adipogen.com/ag-cn2-0051/lovastatin.html ). Potent competitive HMG-CoA reductase inhibitor. Anti-hypercholesterolemic agent. Cholesterol/isoprenoid biosynthesis inhibitor. Blocks the production of mevalonate, a critical compound in the production of cholesterol and isoprenoids. Inhibits the isoprenylation of Ras and Rho family GTPases . Anticancer compound that causes cell cycle arrest in G1 and G2/M phases through modulation of proteasome in cancer cell lines. SKP2 E3 ligase inhibitor. Decreases the expression of Skp2 and results in the inhibition of Skp2-mediated ubiquitination and degradation of p27 and p21, leading to cell cycle arrest and apoptosis. Smooth muscle cell proliferation inhibitor. Anti-adhesive, immunomodulatory and anti-inflammatory compound that stimulates bone formation. Suppresses TNF-induced NF-kappaB activation. Increases cellular resistance to anticancer agents such as doxorubicin and etoposides (Prod. No. AG-CR1-3572 http://www.adipogen.com/ag-cr1-3572/etoposide.html ). Suppresses ICAM-1-LFA-1 interactions, which blocks virus replication and infection. Anti-hypertensive agent.
  • SMILES
    [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • Effects of synvinolin (MK-733) on plasma lipids in familial hypercholesterolaemia: M.J. Mol, et al.; Lancet 2, 936 (1986)
  • All ras proteins are polyisoprenylated but only some are palmitoylated: J.F. Hancock, et al.; Cell 57, 1167 (1989)
  • Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types: P. Negre-Aminou, et al.; Biochim. Biophys. Acta 1345, 259 (1997)
  • Statins as a newly recognized type of immunomodulator: B. Kwak, et al.; Nat. Med. 6, 1399 (2000)
  • Lovastatin and simvastatin are modulators of the proteasome: C. Wojcik, et al.; Int. J. Biochem. Cell Biol. 32, 957 (2000)
  • Statins and bone formation: I.R. Garrett, et al.; Curr. Pharm. Des. 7, 715 (2001)
  • HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection: L.J. Raggatt & N.C. Partridge; Drugs 62, 2185 (2002) (Review)
  • HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis: W.W. Wong, et al.; Leukemia 16, 508 (2002)
  • The statins as anticancer agents: K.K. Chan, et al.; Clin. Cancer Res. 9,10 (2003)
  • Anti-inflammatory and immunomodulatory effects of statins: L.M. Blanco-Colio, et al.; Kidney Int. 63, 12 (2003)